Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
1 report, 1 independent
Updated Sep 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Commission
executive branch of the European Union
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- EMA adopted a positive opinion and the European Commission granted marketing authorization for the drug Hopledo.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- Citigroup involved in global financial markets; India and Canada aiming to close CEPA trade pact; Biocon arm seeks EMA CHMP approval for drug.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.